Letícia Pinheiro Amorim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Letícia Pinheiro Amorim has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Brazil Viana Júnior
Universidade Federal do Ceará
1 shared publication Bartolomeu Feitosa Neto
Liver Transplant Service Walter Cantídio University Hospital Federal University of Ceará Fortaleza Brazil
1 shared publication- Cibele Isaac Saad Rodrigues
Sociedade Brasileira de Nefrologia
1 shared publication - Clébia Azevedo de Lima
Universidade Federal do Ceará
1 shared publication - Eanes Delgado Barros Pereira
Universidade Federal do Ceará
1 shared publication - Elizabeth De Francesco Daher
Universidade Federal do Ceará
1 shared publication
Latest Publications
- 9 February 2026
- Published by Elsevier in Heart & Lung
- Vol. 78, 102732
Impact of electronic cigarette use on blood pressure: A systematic review
- 9 February 2026
- Published by Elsevier in Heart & Lung
- Vol. 78, 102732
Impact of electronic cigarette use on blood pressure: A systematic review
- 28 November 2025
- Published by Wiley in Hepatology Research
- Vol. 56 (3) , 339-350
Autoimmune Hepatitis Profiles After Liver Transplantation in Latin American Patients: A Cluster Analysis of Clinical Outcomes
Aim: Most existing evidence regarding liver transplantation (LT) for autoimmune hepatitis (AIH) originates from European cohorts, hindering the applicability of current guidelines to other populations because of possible geographic variations. There is an urgent need for region‐specific prognostic models. Methods: We analyzed 164 AIH patients from Brazil and Venezuela undergoing LT between 2002 and 2025, the largest AIH LT cohort from Latin America to date. Random survival forests (RSF) identified key predictors of overall survival (OS), graft survival (GS), and AIH recurrence (rAIH). Clustering based on predicted risks identified high‐risk groups with significantly worse outcomes ( p < 0.001 for all). Penalized models with the most important variables from the RSF assessed risk stratification. Results: 5‐, 10‐, and 20‐year OS were 83%, 78%, and 49%. rAIH rates increased from 6% at 5 years to 34% at 20 years. Mycophenolate sodium use in maintenance therapy was ranked as the most important factor for OS (Hazard ratio [HR] = 0.44) and GS (HR = 0.46) prediction, while younger age was the most important risk factor for rAIH. LASSO models accurately predicted early outcomes (1‐year AUCs: OS 0.73, GS 0.73, rAIH 0.81). In a landmark analysis (6 months post‐LT), infectious complications emerged as the main determinant for long‐term OS, and a new model improved 5‐ and 10‐year OS prediction (AUCs: 0.76 and 0.79, respectively). Conclusion: This analysis identifies key predictors that define high‐risk clusters for early and long‐term outcomes in Latin American AIH patients post‐LT, highlighting potential region‐specific factors.
- 28 November 2025
- Published by Wiley in Hepatology Research
- Vol. 56 (3) , 339-350
Autoimmune Hepatitis Profiles After Liver Transplantation in Latin American Patients: A Cluster Analysis of Clinical Outcomes
Aim: Most existing evidence regarding liver transplantation (LT) for autoimmune hepatitis (AIH) originates from European cohorts, hindering the applicability of current guidelines to other populations because of possible geographic variations. There is an urgent need for region‐specific prognostic models. Methods: We analyzed 164 AIH patients from Brazil and Venezuela undergoing LT between 2002 and 2025, the largest AIH LT cohort from Latin America to date. Random survival forests (RSF) identified key predictors of overall survival (OS), graft survival (GS), and AIH recurrence (rAIH). Clustering based on predicted risks identified high‐risk groups with significantly worse outcomes ( p < 0.001 for all). Penalized models with the most important variables from the RSF assessed risk stratification. Results: 5‐, 10‐, and 20‐year OS were 83%, 78%, and 49%. rAIH rates increased from 6% at 5 years to 34% at 20 years. Mycophenolate sodium use in maintenance therapy was ranked as the most important factor for OS (Hazard ratio [HR] = 0.44) and GS (HR = 0.46) prediction, while younger age was the most important risk factor for rAIH. LASSO models accurately predicted early outcomes (1‐year AUCs: OS 0.73, GS 0.73, rAIH 0.81). In a landmark analysis (6 months post‐LT), infectious complications emerged as the main determinant for long‐term OS, and a new model improved 5‐ and 10‐year OS prediction (AUCs: 0.76 and 0.79, respectively). Conclusion: This analysis identifies key predictors that define high‐risk clusters for early and long‐term outcomes in Latin American AIH patients post‐LT, highlighting potential region‐specific factors.